Ming-Ling Chang
Ming-Ling Chang is an expert in Hepatology at Chang Gung Memorial Hospital (Taiwan). As of October 2026, ScienceLeadR ranks Ming-Ling Chang in the top 1% of experts worldwide for Hepatitis. Ming-Ling Chang has authored 169 publications, the most recent in 2026, and is an investigator in 3 clinical trials. SLR score: 539 (community average: 125). How the SLR is computed.
LeadR Profile
Hepatology
Subspecialties: Gastroenterology - Biochemistry - Endocrinology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 169
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Characteristic geoepidemiology and phenotype of autoimmune hepatitis: an 8-year population-based study in Taiwan. PMID 42848155 — liver diseases, diabetes mellitus, hepatitis, autoimmune, mortality, hyperlipidemias, incidence, income, phenotype, liver, prevalence, sex, hepatitis | Hepatol Int | 2026 | 0 |
| Gut Microbiota Recovery After Direct-Acting Antiviral Therapy for Chronic Hepatitis C: A Systematic Review and Meta-Analysis. PMID 42655187 — dysbiosis, hepatitis c, chronic, hepatitis c, recycling, hepatitis, chronic, therapeutics, gastrointestinal microbiome, antiviral agents, microbiota, hepatitis | Microorganisms | 2026 | 0 |
| Pulmonary Vascular Permeability and Extravascular Lung Water Index Vary with Infection Site in Patients with Liver Cirrhosis and Septic Shock. PMID 42652816 — pulmonary edema, mortality, lung, liver cirrhosis, shock, septic, liver, pneumonia, edema, infections | J Clin Med | 2026 | 0 |
| Gastric microbiota composition and its association with rescue eradication outcomes in refractory Helicobacter pylori infection. PMID 42556512 — genes, rrna, helicobacter pylori, helicobacter, therapeutics, microbiota, infections | Biomed J | 2026 | 0 |
| Glucagon-like peptide-1 receptor agonists and advanced liver outcomes in type 2 diabetes: a systematic review and exploratory meta-analysis. PMID 42312204 — diabetes mellitus, glucagon-like peptide 1, carcinoma, hepatocellular, glucagon-like peptide-1 receptor, liver cirrhosis, liver, comparative effectiveness research, glucagon, glucagon-like peptides, diabetes mellitus, type 2 | Front Endocrinol (Lausanne) | 2026 | 0 |
Clinical Studies 3
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map